Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study

Prathibha V K; Mukundan C; Bhagyalekshmi N

doi:10.5455/njppp.2020.10.04081202004042020

2024, Vol: 14, Issue: 4

14 / 4Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Authorship Declaration

« Previous Article

Original Research

Online Publishing Date:
14 / 04 / 2020

Natl J Physiol Pharm Pharmacol. 2020; 10(5): 423-430

doi: 10.5455/njppp.2020.10.04081202004042020

Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study

Prathibha V K, Mukundan C, Bhagyalekshmi N.

Abstract
Background: Altered hemodynamics of heart failure patients is associated with an increased heart rate (HR). The effect of β-blockers on prognosis has been linked to their HR lowering effect. Ivabradine is an If current inhibitor and it decreases the heart rate.

Aims and Objectives: The aim of this study was to compare the efficacy of ivabradine, a combination of ivabradine and metoprolol, with that of metoprolol alone in patients with heart failure.

Materials and Methods: This prospective observational study was done in patients with New York Heart Association (NYHA) Class III/IV heart failure over 18 months. Patients were categorized into Group A: Ivabradine (5 mg BD), Group B: Metoprolol (12.5 mg BD), and Group C: Combination of both (5 mg BD and 12.5 mg BD). At the end of 6 months follow-up, the outcomes of therapy were assessed based on the occurrence of major adverse cardiac events (MACE) such as acute coronary syndrome, rehospitalization, or death. Effectiveness was also measured in terms of a decrease in HR, improvement in left ventricular ejection fraction (LVEF), and NYHA functional class.

Results: One hundred and fifty-two patients were included in this study in three groups 51 patients in Group A, 50 patients in Group B, and 51 patients in Group C. At the end of follow-up period, it was found that the highest number of MACE occurred in Group B followed by A and C. Group C showed significant improvement with therapy in terms of decrease in HR, increase in LVEF, and improvement in NYHA class.

Conclusion: Administration of ivabradine alone or a combination of ivabradine and metoprolol is more effective than metoprolol in reducing the incidence of MACE in heart failure.

Key words: Heart Failure; Heart Rate; Ivabradine; Metoprolol; Major Adverse Cardiac Events; New York Heart Association class

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Prathibha V K Articles by Mukundan C Articles by Bhagyalekshmi N
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

K PV, C M, N B. Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study. Natl J Physiol Pharm Pharmacol. 2020; 10(5): 423-430. doi:10.5455/njppp.2020.10.04081202004042020

Web Style

K PV, C M, N B. Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study. https://www.njppp.com/?mno=96255 [Access: March 14, 2024]. doi:10.5455/njppp.2020.10.04081202004042020

AMA (American Medical Association) Style

K PV, C M, N B. Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study. Natl J Physiol Pharm Pharmacol. 2020; 10(5): 423-430. doi:10.5455/njppp.2020.10.04081202004042020

Vancouver/ICMJE Style

K PV, C M, N B. Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study. Natl J Physiol Pharm Pharmacol. (2020), [cited March 14, 2024]; 10(5): 423-430. doi:10.5455/njppp.2020.10.04081202004042020

Harvard Style

K, P. V., C, . M. & N, . B. (2020) Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study. Natl J Physiol Pharm Pharmacol, 10 (5), 423-430. doi:10.5455/njppp.2020.10.04081202004042020

Turabian Style

K, Prathibha V, Mukundan C, and Bhagyalekshmi N. 2020. Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study. National Journal of Physiology, Pharmacy and Pharmacology, 10 (5), 423-430. doi:10.5455/njppp.2020.10.04081202004042020

Chicago Style

K, Prathibha V, Mukundan C, and Bhagyalekshmi N. "Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study." National Journal of Physiology, Pharmacy and Pharmacology 10 (2020), 423-430. doi:10.5455/njppp.2020.10.04081202004042020

MLA (The Modern Language Association) Style

K, Prathibha V, Mukundan C, and Bhagyalekshmi N. "Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study." National Journal of Physiology, Pharmacy and Pharmacology 10.5 (2020), 423-430. Print. doi:10.5455/njppp.2020.10.04081202004042020

APA (American Psychological Association) Style

K, P. V., C, . M. & N, . B. (2020) Ivabradine alone and in combination with metoprolol reduces the incidence of major adverse cardiac events in patients with heart failure: A prospective study. National Journal of Physiology, Pharmacy and Pharmacology, 10 (5), 423-430. doi:10.5455/njppp.2020.10.04081202004042020

Author Login Reviewer Login About Publisher Editorial Policies Editorial Review Policy Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article


About National Journal of Physiology, Pharmacy and Pharmacology National Journal of Physiology, Pharmacy and Pharmacology is a monthly peer reviewed journal. The journal is having open access polic ... Read more. For best results, please use Internet Explorer or Google Chrome.	Contact Information Publisher publishernjppp@gmail.com Editorial query editornjppp1@gmail.com MOB - 8780040272